More convenient and helpful for colitis patients? An absorption enhancer may do

Sep 19, 2008

Previous studies have shown the beneficial effect of rebamipide, a novel anti-ulcer drug, on experimental colitis. The permeabilities of rebamipide in different intestinal segments remained unknown.

A research article to be published on August 21, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Guo-Feng Li from Nanfang Hospital, Southern Medical University in China investigated the permeability of rabamipide across different intestinal membranes, analyzed potential transportation mode, and observed the effect of sodium laurate (C12) as an absorption enhancer on the permeability of rebamipide across colonic tissues. Furthermore, the effectiveness of chitosan on the colon-specific delivery of rebamipide and the influence of combination chitosan with absorption enhancers on colon specific delivery of rebamipide were explored.

The permeabilities of rebamipide across the jejunal and ileal membranes were higher than the colonic membranes, as monitored by using chamber experiment. Both C12 and labrasol significantly increased permeability of rebamipide across the colon membranes. The release of rebamipide from chitosan capsule was less than 10% totally within 6 h. The areas under concentration-time curve (AUC) in the colon mucosa (AUCLI, 16011.2 ng•h/g) were 2.5 times and 4.4 times greater than using gelatin capsules and CMC suspension, respectively. Meanwhile, AUC in the plasma (AUCPL) were 1016.0 ng•h/mL for chitosan capsule, 1887.9 ng•h/mL for CMC suspension and 2163.5 ng•h/mL for gelatin capsule. The results suggested that both AUCLI and AUCPL increased when C12 was administrated simultaneously, but the increase of AUCLI was much greater; drug delivery index (DDI) was higer in C12 + chitosan than in chitosan capsule group.

Since the present experiments have demonstrated the possibility of chitosan capsule as a specific colon delivery carrier of rebamipide in rats, study of the drug-filled chitosan capsule should be the next step, including large scale preparation and clinical usage. It can be expected that chitosan capsule of rebamipide compounded with absorption enhancer, C12, can be used to treat colnitis effectively in the future.

Source: World Journal of Gastroenterology

Explore further: Cerebral palsy may be hereditary

add to favorites email to friend print save as pdf

Related Stories

Giant garbage patches help redefine ocean boundaries

17 minutes ago

The Great Pacific Garbage Patch is an area of environmental concern between Hawaii and California where the ocean surface is marred by scattered pieces of plastic, which outweigh plankton in that part of ...

New method for non-invasive prostate cancer screening

17 minutes ago

Cancer screening is a critical approach for preventing cancer deaths because cases caught early are often more treatable. But while there are already existing ways to screen for different types of cancer, ...

Clean air halves health costs in Chinese city

1 hour ago

Air pollution regulations over the last decade in Taiyuan, China, have substantially improved the health of people living there, accounting for a greater than 50% reduction in costs associated with loss of life and disability ...

Recommended for you

Travel restrictions could worsen Ebola crisis: experts

17 minutes ago

Travel restrictions could worsen West Africa's Ebola epidemic, limiting medical and food supplies and keeping out much-needed doctors, virologists said Tuesday as the disease continued its deadly spread.

World 'losing the battle' to contain Ebola: MSF

57 minutes ago

International medical agency Medecins sans Frontieres said Tuesday the world was "losing the battle" to contain Ebola and called for a global biological disaster response to get aid and personnel to west Africa.

Mutating Ebola viruses not as scary as evolving ones

1 hour ago

My social media accounts today are cluttered with stories about "mutating" Ebola viruses. The usually excellent ScienceAlert, for example, rather breathlessly informs us "The Ebola virus is mutating faster in humans than in animal hosts ...

War between bacteria and phages benefits humans

2 hours ago

In the battle between our immune systems and cholera bacteria, humans may have an unknown ally in bacteria-killing viruses known as phages. In a new study, researchers from Tufts University, Massachusetts ...

Ebola kills 31 people in DR Congo: WHO

4 hours ago

An outbreak of the Ebola virus in the Democratic Republic of Congo has killed 31 people and the epidemic remains contained in a remote northwestern region, UN the World Health Organization (WHO) said Tuesday.

User comments : 0